.Pharmacolibrary.Drugs.ATC.J.J06BC01 .Pharmacolibrary.Drugs.ATC.J.J06BC01| name: | Nebacumab | |
| ATC code: | J06BC01 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 700 | mg |
| volume of distribution: | 3.5 | L |
| clearance: | 0.2 | L/h |
| other parameters in model implementation | ||
Nebacumab (Centoxin) is a human monoclonal antibody that was developed for treatment of sepsis caused by gram-negative bacteria, specifically targeting endotoxin. The drug was withdrawn from development due to lack of efficacy and is not approved for clinical use today.
No published pharmacokinetic studies in humans available. Parameter estimates are extrapolated based on typical IgG1 monoclonal antibody behavior in adults following intravenous dosing.